290 related articles for article (PubMed ID: 18421033)
1. Surgical complications in a hemophilia patient with factor VIII inhibitor and their endovascular management.
Sadat U; Naik J; Hayes PD
Vasc Endovascular Surg; 2008; 42(2):168-72. PubMed ID: 18421033
[TBL] [Abstract][Full Text] [Related]
2. Hemophilia A pseudoaneurysm in a patient with high responding inhibitors complicating total knee arthroplasty: embolization: a cost-reducing alternative to medical therapy.
Kickuth R; Anderson S; Peter-Salonen K; Lämmle B; Eggli S; Triller J
Cardiovasc Intervent Radiol; 2006; 29(6):1132-5. PubMed ID: 16933159
[TBL] [Abstract][Full Text] [Related]
3. Postpartum acquired factor VIII inhibitors.
Franchini M
Am J Hematol; 2006 Oct; 81(10):768-73. PubMed ID: 16868941
[TBL] [Abstract][Full Text] [Related]
4. Management of joint bleeding in hemophilia.
Simpson ML; Valentino LA
Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238
[TBL] [Abstract][Full Text] [Related]
5. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors.
Leissinger CA; Singleton T; Kruse-Jarres R
Blood; 2015 Jul; 126(2):153-9. PubMed ID: 25827834
[TBL] [Abstract][Full Text] [Related]
6. Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol.
Ilonczai P; Schlammadinger A; Oláh Z; Rázsó K; Bereczky Z; Boda Z
Thromb Haemost; 2008 Jul; 100(1):149-50. PubMed ID: 18612550
[No Abstract] [Full Text] [Related]
7. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
8. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
Sultan Y; Brouet JC
Nouv Presse Med; 1975 Oct; 4(36):2571-4. PubMed ID: 1081682
[TBL] [Abstract][Full Text] [Related]
10. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
11. Surgery in haemophilic patients with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
[No Abstract] [Full Text] [Related]
12. Successful endoscopic sphincterotomy for choledocholithiasis in a patient with severe hemophilia A and inhibitors.
Sugiura R; Kuwatani M; Kawakubo K; Sano I; Kato S; Endo T; Sakamoto N
Clin J Gastroenterol; 2018 Jun; 11(3):188-192. PubMed ID: 29396835
[TBL] [Abstract][Full Text] [Related]
13. Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: a case report.
Kubisz P; Plamenová I; Stasko J; Dobrotová M; Hollý P
Thromb Haemost; 2010 Apr; 103(4):868-70. PubMed ID: 20135075
[No Abstract] [Full Text] [Related]
14. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
15. Severe postoperative haemarthrosis following a total knee replacement in a haemophiliac patient caused by a pseudoaneurysm: early treatment with arterial embolization.
Rodriguez-Merchan EC; Jimenez-Yuste V; Gomez-Cardero P; Rodriguez T
Haemophilia; 2014 Jan; 20(1):e86-9. PubMed ID: 24165398
[No Abstract] [Full Text] [Related]
16. Octocog alfa (Advate®): a guide to its use in hemophilia A.
Keating GM; Dhillon S
BioDrugs; 2012 Aug; 26(4):269-73. PubMed ID: 22759264
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.
Santagostino E; Lalezari S; Reding MT; Ducore J; Ng HJ; Poulsen LH; Michaels LA; Linardi CCG
Thromb Res; 2019 Nov; 183():13-19. PubMed ID: 31513978
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
Ragni MV; Alabek M; Malec LM
Haemophilia; 2016 Sep; 22(5):e462-4. PubMed ID: 27501368
[No Abstract] [Full Text] [Related]
19. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
20. The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.
Leissinger CA
Am J Hematol; 2012 May; 87 Suppl 1():S23-6. PubMed ID: 22473571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
